PYC, page-23

We'd better get a move on with that omomyc equivalent. Sounds like the creators are making progress.

Presentation for American association of cancer research made in April 2015 apparently. Part of the summary below.
First therapy is a omomyc peptide applied via intranasal administration, seen to have a therapeutic effect.
Second therapy research method involves "nanocarrier technology" that can be used to deliver omomyc systematically and can be combined with tumor targetting legands. Sounds like exactly what we need. I wonder if pyc are reading this.

Im actually surprised they release this amount of information when it appears they are still developing the therapy. Surely you would get everything patented first?? I wonder what else we have other than myc inhibitors if we miss out there.

http://www.abstractsonline.com/plan...ce&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424#

Part pasted below

"Here we discuss our current research with
Omomyc and our efforts to develop a clinically viable approach to Myc inhibition. One is based on the direct use of Omomyc itself as a peptide since we have discovered that it natively possesses cell-penetrating activity and it rapidly biodistributes to the lung and brain after intranasal administration. We are finding that the Omomyc peptide - like its transgenic counterpart before - has a therapeutic impact and we are continuing with the preclinical validation of this innovative therapeutic approach to pharmacological Myc inhibition. The second approach takes advantage of state-of-the-art nanocarrier technology to deliver Omomyc systemically, that can be combined with tumour-targeting ligands. These two novel Myc inhibition strategies have the potential to be translated rapidly to the clinic."